Challenges in the diagnosis of diabetes type in pediatrics.
MODY
delayed diagnosis
diabetes complications
diabetes mellitus
pediatrics
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
03
2020
revised:
07
05
2020
accepted:
10
06
2020
pubmed:
21
6
2020
medline:
19
11
2021
entrez:
21
6
2020
Statut:
ppublish
Résumé
The incidence of diabetes, both type 1 and type 2, is increasing. Health outcomes in pediatric diabetes are currently poor, with trends indicating that they are worsening. Minority racial/ethnic groups are disproportionately affected by suboptimal glucose control and have a higher risk of acute and chronic complications of diabetes. Correct clinical management starts with timely and accurate classification of diabetes, but in children this is becoming increasingly challenging due to high prevalence of obesity and shifting demographic composition. The growing obesity epidemic complicates classification by obesity's effects on diabetes. Since the prevalence and clinical characteristics of diabetes vary among racial/ethnic groups, migration between countries leads to changes in the distribution of diabetes types in a certain geographical area, challenging the clinician's ability to classify diabetes. These challenges must be addressed to correctly classify diabetes and establish an appropriate treatment strategy early in the course of disease for all. This may be the first step in improving diabetes outcomes across racial/ethnic groups. This review will discuss the pitfalls in the current diabetes classification scheme that is leading to increasing overlap between diabetes types and heterogeneity within each type. It will also present proposed alternative classification schemes and approaches to understanding diabetes type that may improve the timely and accurate classification of pediatric diabetes type.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1064-1073Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Dabelea D, Hamman RF, Knowler WC. Diabetes in Youth. In: Cowie CC, Casagrande SS, Menke A, et al. Diabetes in America. 17-1468. 3rd Ed, Bethesda, MD: National Institutes of Health, NIH Pub; 2018;15-1-15-54.
Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408-417.
Ke C, Sohal P, Qian H, Quan H, Khan NA. Diabetes in the young: a population-based study of south Asian, Chinese and white people. Diabet Med. 2015;32(4):487-496.
Candler TP, Mahmoud O, Lynn RM, Majbar AA, Barrett TG, Shield JPH. Continuing rise of type 2 diabetes incidence in children and young people in the UK. Diabet Med. 2018;35(6):737-744.
Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among north adolescents: an epidemiologic health perspective. J Pediatr. 2000;136(5):664-672.
Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Type 2 diabetes in Asian-Indian urban children. Diabetes Care. 2003;26(4):1022-1025.
Urakami T, Miyata M, Yoshida K, et al. Changes in annual incidence of school children with type 2 diabetes in the Tokyo metropolitan area during 1975-2015. Pediatr Diabetes. 2018;19(8):1385-1392.
Imperatore G, Boyle JP, Thompson TJ, et al. Projections of type 1 and type 2 diabetes burden in the US population aged< 20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012;35(12):2515-2520.
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;376(15):1419-1429.
Fu J-F, Liang L, Gong C-X, et al. Status and trends of diabetes in Chinese children: analysis of data from 14 medical centers. World J Pediatr. 2013;9(2):127-134.
Ferrara CT, Geyer SM, Liu Y-F, et al. Excess BMI in childhood: a modifiable risk factor for type 1 diabetes development? Diabetes Care. 2017;40(5):698-701.
Censin JC, Nowak C, Cooper N, Bergsten P, Todd JA, Fall T. Childhood adiposity and risk of type 1 diabetes: a Mendelian randomization study. PLoS Med. 2017;14(8):e1002362.
Ferrara CT, Geyer SM, Evans-Molina C, et al. The role of age and excess body mass index in progression to type 1 diabetes in at-risk adults. J Clin Endocrinol Metab. 2017;102(12):4596-4603.
Brooks-Worrell BM, Palmer JP. Setting the stage for islet autoimmunity in type 2 diabetes: obesity-associated chronic systemic inflammation and endoplasmic reticulum (ER) stress. Diabetes Care. 2019;42(12):2338-2346.
Ogden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. JAMA. 2016;315(21):2292-2299.
Tosur M, Geyer SM, Rodriguez H, et al. Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk. Diabetologia. 2018;61(9):2043-2053.
Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2015;15(17):1.
Anderson BJ, Laffel LM, Domenger C, et al. Factors associated with diabetes-specific health-related quality of life in youth with type 1 diabetes: the Global TEENs Study. Diabetes Care. 2017;40(8):1002-1009.
Dall TM, Yang W, Gillespie K, et al. The economic burden of elevated blood glucose levels in 2017: diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes. Diabetes Care. 2019;42(9):1661-1668.
American Diabetes Association. Economic costs of diabetes in the US in 2017. Diabetes Care. 2018;41:917.
Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for diabetes in youth study: rationale, findings, and future directions. Diabetes Care. 2014;37(12):3336-3344.
Zeitler P, Arslanian S, Fu J, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19:28-46.
Khanolkar AR, Amin R, Taylor-Robinson D, Viner R, Warner J, Stephenson T. Ethnic minorities are at greater risk for childhood-onset type 2 diabetes and poorer glycemic control in England and Wales. J Adolesc Health. 2016;59(3):354-361.
Nirantharakumar K, Mohammed N, Toulis KA, Thomas GN, Narendran P. Clinically meaningful and lasting HbA 1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis. Diabetologia. 2018;61(5):1064-1070.
Redondo MJ, Libman I, Cheng P, et al. Racial/ethnic minority youth with recent-onset type 1 diabetes have poor prognostic factors. Diabetes Care. 2018;41(5):1017-1024.
World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(suppl 1):S14-S31.
Steck AK, Winter WE. Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes. 2011;18(4):252-258.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2018. Diabetes Care. 2018;41(suppl 1):S73-S85.
Bacha F. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children. Lancet Child Adolesc Health. 2019;3(9):595-597.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637-646.
American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27(suppl 1):s88-s90.
Carmody D, Naylor RN, Bell CD, et al. GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016;53(5):703-708.
Anık A, Çatlı G, Abacı A, Böber E. Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab. 2015;28(3-4):251-263.
Ellard S, Bellanné-Chantelot C, Hattersley AT, European Molecular Genetics Quality Network (EMQN) MODY Group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546-553.
Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):769-777.
Mohan V, Radha V. Precision diabetes is slowly becoming a reality. Med Princ Pract. 2019;28(1):1-9.
SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for diabetes in youth study. Pediatrics. 2006;118(4):1510-1518.
Hutchins J, Barajas RA, Hale D, Escaname E, Lynch J. Type 2 diabetes in a 5-year-old and single center experience of type 2 diabetes in youth under 10. Pediatr Diabetes. 2017;18(7):674-677.
Nadeau KJ, Anderson BJ, Berg EG, et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care. 2016;39(9):1635-1642.
Kaminski BM, Klingensmith GJ, Beck RW, et al. Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr. 2013;162(4):736-740.
Gandhi K, Tosur M, Schaub R, Haymond MW, Redondo MJ. Racial and ethnic differences among children with new-onset autoimmune type 1 diabetes. Diabet Med. 2017;34(10):1435-1439.
Redondo MJ, Rodriguez LM, Escalante M, O'Brian Smith E, Balasubramanyam A, Haymond MW. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes. 2012;13(7):564-571.
Redondo MJ, Foster NC, Libman IM, et al. Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index. Acta Diabetol. 2016;53(2):271-277.
Redondo MJ, Rodriguez LM, Haymond MW, et al. Serum adiposity-induced biomarkers in obese and lean children with recently diagnosed autoimmune type 1 diabetes. Pediatr Diabetes. 2014;15(8):543-549.
Rivera-Vega MY, Flint A, Winger DG, Libman I, Arslanian S. Obesity and youth diabetes: distinguishing characteristics between islet cell antibody positive vs. negative patients over time. Pediatr Diabetes. 2015;16(5):375-381.
Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia. 2004;47(10):1661-1667.
Bingley PJ, Mahon JL, Gale EAM. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care. 2008;31(1):146-150.
Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care. 2007;30(9):2314-2320.
Couper JJ, Beresford S, Hirte C, et al. Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care. 2009;32(1):94-99.
Nokoff N, Rewers M. Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann N Y Acad Sci. 2013;1281(1):1-15.
Larsson HE, Vehik K, Haller MJ, et al. Growth and risk for islet autoimmunity and progression to type 1 diabetes in early childhood: the environmental determinants of diabetes in the Young Study. Diabetes. 2016;65(7):1988-1995.
Ferrara-Cook C, Geyer SM, Evans-Molina C, et al. Excess BMI accelerates islet autoimmunity in older children and adolescents. Diabetes Care. 2020;43(3):580-587.
Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38(3):476-481.
Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066-2073.
Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ. Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose. Diabetes Care. 2016;39(10):1664-1670.
Cengiz E, Cheng P, Ruedy KJ, et al. Clinical outcomes in youth beyond the first year of type 1 diabetes: results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatr Diabetes. 2017;18(7):566-573.
Redondo MJ, Connor CG, Ruedy KJ, et al. Pediatric diabetes consortium type 1 diabetes new onset (NeOn) study: factors associated with HbA1c levels one year after diagnosis. Pediatr Diabetes. 2014;15(4):294-302.
Maahs DM, Hermann JM, Holman N, et al. Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the US, Austria, and Germany. Diabetes Care. 2015;38(10):1876-1882.
TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care. 2013;36(6):1765-1771.
Klingensmith GJ, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes. 2016;17(4):266-273.
American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(suppl 1):S11-S24.
Arslanian S, Kim JY, Bacha F, et al. The shape of the glucose response curve during an oral glucose tolerance test: forerunner of heightened glycemic failure rates and accelerated decline in β-cell function in TODAY. Diabetes Care. 2019;42(1):164-172.
Pinhas-Hamiel O, Zeitler P. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes. 2007;8:16-27.
McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med. 2001;18(1):10-16.
D'Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care. 2011;34(suppl 2):S161-S165.
TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-2256.
Mortensen HB, Hougaard P, Swift P, et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384-1390.
Shields BM, Shepherd M, Hudson M, et al. Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care. 2017;40(8):1017-1025.
Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2009;10:33-42.
Redondo MJ, Rodriguez LM, Escalante M, Smith EO, Balasubramanyam A, Haymond MW. Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis. Pediatr Diabetes. 2013;14(5):333-340.
Gerard-Gonzalez A, Gitelman SE, Cheng P, et al. Comparison of autoantibody-positive and autoantibody-negative pediatric participants enrolled in the T1D exchange clinic registry. J Diabetes. 2013;5(2):216-223.
Zeitler P. Update on nonautoimmune diabetes in children. J Clin Endocrinol Metab. 2009;94(7):2215-2220.
Knip M, Korhonen S, Kulmala P, et al. Prediction of type 1 diabetes in the general population. Diabetes Care. 2010;33(6):1206-1212.
Hameed S, Ellard S, Woodhead HJ, et al. Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children. Pediatr Diabetes. 2011;12(3 pt 1):142-149.
Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care. 2010;33(9):1970-1975.
Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet. 1997;350(9087):1288-1293.
Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab. 2013;98(10):4055-4062.
Chambers C, Fouts A, Dong F, et al. Characteristics of maturity onset diabetes of the young in a large diabetes center. Pediatr Diabetes. 2016;17(5):360-367.
Kleinberger JW, Copeland KC, Gandica RG, et al. Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med. 2018;20(6):583-590.
Shepherd M, Shields B, Hammersley S, et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the UKpediatric diabetes population with monogenic diabetes. Diabetes Care. 2016;39(11):1879-1888.
Glotov OS, Serebryakova EA, Turkunova ME, et al. Whole-exome sequencing in Russian children with non-type 1 diabetes mellitus reveals a wide spectrum of genetic variants in MODY-related and unrelated genes. Mol Med Rep. 2019;20(6):4905-4914.
Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015;1353(1):113-137.
Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(suppl 2):S151-S156.
Aye T, Mazaika PK, Mauras N, et al. Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care. 2019;42(3):443-449.
Siller AF, Lugar H, Rutlin J, et al. Severity of clinical presentation in youth with type 1 diabetes is associated with differences in brain structure. Pediatr Diabetes. 2017;18(8):686-695.
Semenkovich K, Bischoff A, Doty T, et al. Clinical presentation and memory function in youth with type 1 diabetes. Pediatr Diabetes. 2016;17(7):492-499.
Cameron FJ, Scratch SE, Nadebaum C, et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care. 2014;37(6):1554-1562.
Chang L-H, Lin L-Y, Tsai M-T, et al. Association between hyperglycaemic crisis and long-term major adverse cardiovascular events: a nationwide population-based, propensity score-matched, cohort study. BMJ Open. 2016;6(8):e012233.
Duca LM, Reboussin BA, Pihoker C, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study. Pediatr Diabetes. 2019;20(2):172-179.
Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care. 2017;40(9):1249-1255.
Bowden SA, Duck MM, Hoffman RP. Young children (< 5 yr) and adolescents (> 12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008;9(3pt1):197-201.
Rudberg S, Ullman E, Dahlquist G. Relationship between early metabolic control and the development of microalbuminuria-a longitudinal study in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1993;36(12):1309-1314.
Dias J, Martins S, Carvalho S, Marques O, Antunes A. Mauriac syndrome still exists. Endocrinol Nutr. 2013;60(5):245-248.
Fox LA, Hershey T, Mauras N, et al. Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia. 2018;61(7):1538-1547.
Murillo M, Bel J, Pérez J, et al. Health-related quality of life (HRQOL) and its associated factors in children with type 1 diabetes mellitus (T1DM). BMC Pediatr. 2017;17(1):16.
American Diabetes Association. Summary of revisions: standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42(suppl 1):S4-S6.
Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA 1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 2010;53(6):1093-1098.
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial. Arch Ophthalmol. 2008;126(12):1707.
Ceriello A, Ihnat MA, Thorpe JE. The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94(2):410-415.
Pop-Busui R, Herman WH, Feldman EL, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010;10(4):276-282.
Waki H, Yamauchi T, Kadowaki T. The epigenome and its role in diabetes. Curr Diab Rep. 2012;12(6):673-685.
Ce GV, Rohde LE, da Silva AMV, Coutinho MKP, de Castro AC, Bertoluci MC. Endothelial dysfunction is related to poor glycemic control in adolescents with type 1 diabetes under 5 years of disease: evidence of metabolic memory. J Clin Endocrinol Metab. 2011;96(5):1493-1499.
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64(2):631-642.
Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16.
Chen Z, Miao F, Paterson AD, et al. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci U S A. 2016;113(21):E3002-E3011.
Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia. 2016;59(1):13-20.
Wu Y-L, Ding Y-P, Gao J, Tanaka Y, Zhang W. Risk factors and primary prevention trials for type 1 diabetes. Int J Biol Sci. 2013;9(7):666.
Ziegler A-G, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010;32(4):468-478.
Florez JC. Precision medicine in diabetes: is it time? Diabetes Care. 2016;39(7):1085-1088.
Tripathi A, Rizvi AA, Knight LM, Jerrell JM. Prevalence and impact of initial misclassification of pediatric type 1 diabetes mellitus. South Med J. 2012;105(10):513-517.
Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. Type 2 diabetes mellitus in the child and adolescent. Pediatr Diabetes. 2008;9(5):512-526.
Young-Hyman D, De Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(12):2126-2140.
Abdoli S, Jones DH, Vora A, Stuckey H. Improving diabetes care: should we reconceptualize diabetes burnout? Diabetes Educ. 2019;45(2):214-224.
Borus JS, Laffel L. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. Curr Opin Pediatr. 2010;22(4):405-411.
Markowitz JT, Pratt K, Aggarwal J, Volkening LK, Laffel LMB. Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth. Diabetes Technol Ther. 2012;14(6):523-526.
Young MT, Lord JH, Patel NJ, Gruhn MA, Jaser SS. Good cop, bad cop: quality of parental involvement in type 1 diabetes management in youth. Curr Diab Rep. 2014;14(11):546.
Williams LB, Laffel LMB, Hood KK. Diabetes-specific family conflict and psychological distress in paediatric type 1 diabetes. Diabet Med. 2009;26(9):908-914.
Shepherd MH, Shields BM, Hudson M, et al. A UKnationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia. 2018;61(12):2520-2527.
Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317(8):825-835.
Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for diabetes in youth study. Diabetes Care. 2011;34(7):1628-1633.
Balasubramanyam A, Garza G, Rodriguez L, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006;29(12):2575-2579.
McCarthy MI. Painting a new picture of personalised medicine for diabetes. Diabetologia. 2017;60(5):793-799.
Wasserfall C, Nead K, Mathews C, Atkinson MA. The threshold hypothesis: solving the equation of nurture vs nature in type 1 diabetes. Diabetologia. 2011;54(9):2232.
Battaglia M, Anderson MS, Buckner JH, et al. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017;60(11):2139-2147.
Battaglia M, Ahmed S, Anderson MS, et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care. 2020;43(1):5-12.
Redondo MJ, Kawasaki E, Mulgrew CL, et al. DR-and DQ-associated protection from type 1A diabetes: comparison of DRB11401 and DQA10102-DQB10602. J Clin Endocrinol Metab. 2000;85(10):3793-3797.
Aly TA, Ide A, Humphrey K, et al. Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with type 1A diabetes. J Autoimmun. 2005;25:40-45.
Redondo MJ, Fain PR, Krischer JP, et al. Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes. J Autoimmun. 2004;23(3):275-279.
Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med. 2008;359(26):2849-2850.
Redondo MJ, Yu L, Hawa M, et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia. 2001;44(3):354-362.
Redondo MJ, Babu S, Zeidler A, et al. Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab. 2006;91(5):1705-1713.
Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(1):a007732.
Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331-2339.
Steck AK, Bugawan TL, Valdes AM, et al. Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes. 2005;54(8):2482-2486.
Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ. 1999;318(7185):698-702.
Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A diabetes. Recent Prog Horm Res. 2001;56:69-89.
Gale EAM, Bingley PJ, Eisenbarth GS, Redondo MJ, Kyvik KO, Petersen JS. Reanalysis of twin studies suggests that diabetes is mainly genetic. BMJ. 2001;323(7319):997.
Redondo MJ, Eisenbarth GS. Genetic control of autoimmunity in type I diabetes and associated disorders. Diabetologia. 2002;45(5):605-622.
Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care. 2016;39(3):337-344.
Patel KA, Oram RA, Flanagan SE, et al. Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. Diabetes. 2016;65(7):2094-2099.
Florez JC. Found in translation: a type 1 diabetes genetic risk score applied to clinical diagnosis. Diabetes Care. 2016;39(3):330-332.
Grubb AL, McDonald TJ, Rutters F, et al. A type 1 diabetes genetic risk score can identify patients with GAD65 autoantibody-positive type 2 diabetes who rapidly progress to insulin therapy. Diabetes Care. 2019;42(2):208-214.
Sharp SA, Rich SS, Wood AR, et al. Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care. 2019;42(2):200-207.
Perry DJ, Wasserfall CH, Oram RA, et al. Application of a genetic risk score to racially diverse type 1 diabetes populations demonstrates the need for diversity in risk-modeling. Sci Rep. 2018;8(1):4529.
Onengut-Gumuscu S, Chen W-M, Robertson CC, et al. Type 1 diabetes risk in African-ancestry participants and utility of an ancestry-specific genetic risk score. Diabetes Care. 2019;42(3):406-415.
Redondo MJ, Geyer S, Steck AK, et al. A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care. 2018;41(9):1887-1894.
Bansal N, Hampe CS, Rodriguez L, et al. DPD epitope-specific glutamic acid decarboxylase (GAD) 65 autoantibodies in children with type 1 diabetes. Diabet Med. 2017;34(5):641-646.
Redondo MJ, Muniz J, Rodriguez LM, et al. Association of TCF7L2 variation with single islet autoantibody expression in children with type 1 diabetes. BMJ Open Diabetes Res Care. 2014;2(1):e000008.
Redondo MJ, Grant SFA, Davis A, Greenbaum C, Biobank TE. Dissecting heterogeneity in paediatric type 1 diabetes: association of TCF7L2 rs7903146 TT and low-risk human leukocyte antigen (HLA) genotypes. Diabet Med. 2017;34(2):286-290.
Redondo MJ, Shirkey BA, Fraga DW, Gaber AO, Sabek OM. Serum undercarboxylated osteocalcin correlates with hemoglobin A1c in children with recently diagnosed pediatric diabetes. Pediatr Diabetes. 2017;18(8):869-873.
Redondo MJ. LADA: time for a new definition. Diabetes. 2013;62(2):339-340.
Ennis SR, Ríos-Vargas M, Albert NG. The hispanic population: 2010. US Department of Commerce, Economics and Statistics Administration US Census Bureau. http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf.
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.